Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderich E Schwarz

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|May 26, 2023
Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical modelsNiranjan Awasthi, Margaret A Schwarz, Quinn Kaurich, et al.
Surgery Open Science|June 5, 2023
Low incisional hernia incidence using a large-bite, low-tension technique for celiotomy closureJoy Sarkar, Michael J Minarich, Levi Y Smucker, et al.
The American Journal of Surgical Pathology|February 24, 2005
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2Peiguo G Chu, Roderich E Schwarz, Sean K Lau, et al.
Cancer Biology & Therapy|March 10, 2010
Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferationRoderich E Schwarz, Niranjan Awasthi, Srivani Konduri, et al.
Cancer Research|August 4, 2004
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1Gayathri Subramanian, Roderich E Schwarz, Linda Higgins, et al.
Molecular Cancer Therapeutics|March 11, 2014
Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancerNiranjan Awasthi, Changhua Zhang, Anna M Schwarz, et al.
World Journal of Oncology|November 18, 2017
Clinical Evidence: Metastases can MetastasizeGregory A Stanley, Jyoti P Balani, David S Miller, et al.
Biochemical Pharmacology|September 18, 2002
Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 statusAaron B Coleman, Marianne Z Metz, Cécile A Donohue, et al.
American Journal of Clinical Oncology|June 1, 2002
Long-term survival after radical operations for cancer treatment-induced sarcomas: how two survivors invite reflection on oncologic treatment conceptsRoderich E Schwarz, Georg Hillebrand, Elizabeth A Peralta, et al.
Oncotarget|April 30, 2016
Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer modelsNiranjan Awasthi, Emily Scire, Sheena Monahan, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|May 26, 2023
Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical modelsNiranjan Awasthi, Margaret A Schwarz, Quinn Kaurich, et al.
Surgery Open Science|June 5, 2023
Low incisional hernia incidence using a large-bite, low-tension technique for celiotomy closureJoy Sarkar, Michael J Minarich, Levi Y Smucker, et al.
The American Journal of Surgical Pathology|February 24, 2005
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2Peiguo G Chu, Roderich E Schwarz, Sean K Lau, et al.
Cancer Biology & Therapy|March 10, 2010
Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferationRoderich E Schwarz, Niranjan Awasthi, Srivani Konduri, et al.
Cancer Research|August 4, 2004
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1Gayathri Subramanian, Roderich E Schwarz, Linda Higgins, et al.
Molecular Cancer Therapeutics|March 11, 2014
Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancerNiranjan Awasthi, Changhua Zhang, Anna M Schwarz, et al.
World Journal of Oncology|November 18, 2017
Clinical Evidence: Metastases can MetastasizeGregory A Stanley, Jyoti P Balani, David S Miller, et al.
Biochemical Pharmacology|September 18, 2002
Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 statusAaron B Coleman, Marianne Z Metz, Cécile A Donohue, et al.
American Journal of Clinical Oncology|June 1, 2002
Long-term survival after radical operations for cancer treatment-induced sarcomas: how two survivors invite reflection on oncologic treatment conceptsRoderich E Schwarz, Georg Hillebrand, Elizabeth A Peralta, et al.
Oncotarget|April 30, 2016
Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer modelsNiranjan Awasthi, Emily Scire, Sheena Monahan, et al.
Pageof 11